We Are Crinetics


Crinetics is a pharmaceutical company founded in endocrinology research. Our intense focus is on developing much-needed therapies for people with endocrine diseases and endocrine-related tumors. For us, it’s all about these underserved patients, who are eager to find therapies that provide effective disease control and bring more simplicity to their lives. To better achieve these goals, we also partner with endocrinologists and other healthcare practitioners to ensure we’re solving real problems for them.

Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1)
Acromegaly (PATHFNDR-2)
Carcinoid Syndrome
Congenital Adrenal Hyperplasia (CAH)
PTH Antagonist, Hyperparathyroidism
SST3 Agonist, Polycystic Kidney Disease
TSH Antagonist, Graves' Disease, TED
Oral GLP-1 nonpeptide, Diabetes, Obesity
Oral GIP nonpeptide, Diabetes, Obesity
SST5 Agonist, Hyperinsulinism
Radionetics, Targeted Radiotherapy | Multiple Solid-Tumor Oncology Company
Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1)
Acromegaly (PATHFNDR-2)
Carcinoid Syndrome
Congenital Adrenal Hyperplasia (CAH)
PTH Antagonist, Hyperparathyroidism
Undisclosed, Polycystic Kidney
TSH Antagonist, Graves' Disease, TED
Undisclosed (Multiple), Diabetes, Obesity
SST5 Agonist, Hyperinsulinism
Radionetics, Targeted Radiotherapy | Multiple Solid-Tumor Oncology Company

Session SP002: June 15, 10:00 AM - 11:00 AMW-375A (ENDO Main Stage)


Crinetics CEO Scott Struthers, Ph.D., accepts the John D. Baxter Prize for Entrepreneurship and presents on the "Adventures Discovering Nonpeptide Oral Drugs Acting at Peptide Hormone Receptors".

Learn More
scott baxter prize uai

Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oral Paltusotine, a Non-Peptide, Selective Somatostatin Receptor Subtype 2 Agonist
Rosa Luo, MS; Alessandra Casagrande, MD, PhD; Sonic Oun, BA; Yang Wang, MSPH; R. Scott Struthers, PhD; Alan Krasner, MD
Crinetics Pharmaceuticals Inc., San Diego, CA, USA

The Use of Salivary Cortisol Measurement by Mass Spectrometry to Identify Low Serum Cortisol Values in Healthy Volunteers Receiving CRN04894, A Melanocortin 2 Receptor (MC2R) Antagonist
Alejandro Ayala, MD; Carl LaCerte, MS; Rosa Luo, MS; Christopher Davidson, MS; Jian Wang, PhD; Peter Trainer, MD; Alan Krasner, MD
Crinetics Pharmaceuticals Inc., San Diego, CA, USA

Discovery and Characterization of Orally Bioavailable Nonpeptide Thyroid Stimulating Hormone Receptor (TSHR) Antagonists for the Treatment of Graves’ Disease
Melissa A. Fowler, Collin Regan, Jian Zhao, Eulalia Coutinho, Beth Fleck, Michael Johns, Yang Tang, Emmanuel Sturchler, Mi Chen, Kelsey Retting, Deepak Dalvie, Stephen F. Betz, Stacy Markison
Crinetics Pharmaceuticals, San Diego, CA

Effects of an Orally Bioavailable Nonpeptide Parathyroid Hormone Receptor Type 1 (PTH1R) Antagonist in Rodent Models of Primary Hyperparathyroidism (PHPT)
Agnes S. Antwan, Elizabeth Rico-Bautista, Joseph Pontillo, Shimiao Wang, Michael A .Johns, Bastian Ramms, Melissa A. Fowler, Julie B. Nguyen, Anel A. Castellanos Gonzalez, Beth Fleck, Kelsey Retting, Deepak Dalvie, Stephen F. Betz, Stacy Markison
Crinetics Pharmaceuticals, San Diego, CA.

Pipeline

Connect With Us


Please complete this form to be contacted directly by a member of our medical affairs team.